Self-reported depressive symptom measures: Sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients

A. John Rush, Madhukar H. Trivedi, Thomas J. Carmody, Hisham H. Ibrahim, John C. Markowitz, Gabor I. Keitner, Susan G. Kornstein, Bruce Arnow, Daniel N. Klein, Rachel Manber, David L. Dunner, Alan J. Gelenberg, James H. Kocsis, Charles B. Nemeroff, Jan Fawcett, Michael E. Thase, James M. Russell, Darlene N. Jody, Frances O. Borian, Martin B. Keller

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-1) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-1, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a ≥50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-1 score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-1), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-1), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR 16), 73% (PGI-1), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30 = 32%, QIDS-SR 16 = 28%, PGI-1 = 22%, HDRS17 = 30%), for CBASP (IDS-SR30 = 32%, QIDS-SR16 = 30%, PGI-1 = 21%, HDRS 17 = 32%), and for the combination (IDS-SR30 = 52%, QIDS-SR16 = 50%, PGI-1 = 25%, HDRS17 = 49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-1, as opposed to specific item-based ratings, provide less valid findings.

Original languageEnglish (US)
Pages (from-to)405-416
Number of pages12
JournalNeuropsychopharmacology
Volume30
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Self Report
Outpatients
Randomized Controlled Trials
Psychotherapy
Depression
Equipment and Supplies
Costs and Cost Analysis
Therapeutics
nefazodone

Keywords

  • Chronic depression
  • Nefazodone
  • Psychotherapy
  • Symptom measures

ASJC Scopus subject areas

  • Pharmacology

Cite this

Self-reported depressive symptom measures : Sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. / Rush, A. John; Trivedi, Madhukar H.; Carmody, Thomas J.; Ibrahim, Hisham H.; Markowitz, John C.; Keitner, Gabor I.; Kornstein, Susan G.; Arnow, Bruce; Klein, Daniel N.; Manber, Rachel; Dunner, David L.; Gelenberg, Alan J.; Kocsis, James H.; Nemeroff, Charles B.; Fawcett, Jan; Thase, Michael E.; Russell, James M.; Jody, Darlene N.; Borian, Frances O.; Keller, Martin B.

In: Neuropsychopharmacology, Vol. 30, No. 2, 02.2005, p. 405-416.

Research output: Contribution to journalArticle

Rush, AJ, Trivedi, MH, Carmody, TJ, Ibrahim, HH, Markowitz, JC, Keitner, GI, Kornstein, SG, Arnow, B, Klein, DN, Manber, R, Dunner, DL, Gelenberg, AJ, Kocsis, JH, Nemeroff, CB, Fawcett, J, Thase, ME, Russell, JM, Jody, DN, Borian, FO & Keller, MB 2005, 'Self-reported depressive symptom measures: Sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients', Neuropsychopharmacology, vol. 30, no. 2, pp. 405-416. https://doi.org/10.1038/sj.npp.1300614
Rush, A. John ; Trivedi, Madhukar H. ; Carmody, Thomas J. ; Ibrahim, Hisham H. ; Markowitz, John C. ; Keitner, Gabor I. ; Kornstein, Susan G. ; Arnow, Bruce ; Klein, Daniel N. ; Manber, Rachel ; Dunner, David L. ; Gelenberg, Alan J. ; Kocsis, James H. ; Nemeroff, Charles B. ; Fawcett, Jan ; Thase, Michael E. ; Russell, James M. ; Jody, Darlene N. ; Borian, Frances O. ; Keller, Martin B. / Self-reported depressive symptom measures : Sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. In: Neuropsychopharmacology. 2005 ; Vol. 30, No. 2. pp. 405-416.
@article{7356e16183ec489ba8d5c6281cabf6ea,
title = "Self-reported depressive symptom measures: Sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients",
abstract = "This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-1) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-1, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a ≥50{\%} reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-1 score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41{\%} (IDS-SR30), 45{\%} (QIDS-SR16), 53{\%} (PCI-1), and 47{\%} (HDRS17). For CBASP, response rates were 41{\%} (IDS-SR30), 45{\%} (QIDS-SR16), 48{\%} (PGI-1), and 46{\%} (HDRS17). For the combination, response rates were 68{\%} (IDS-SR30 and QIDS-SR 16), 73{\%} (PGI-1), and 76{\%} (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30 = 32{\%}, QIDS-SR 16 = 28{\%}, PGI-1 = 22{\%}, HDRS17 = 30{\%}), for CBASP (IDS-SR30 = 32{\%}, QIDS-SR16 = 30{\%}, PGI-1 = 21{\%}, HDRS 17 = 32{\%}), and for the combination (IDS-SR30 = 52{\%}, QIDS-SR16 = 50{\%}, PGI-1 = 25{\%}, HDRS17 = 49{\%}). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-1, as opposed to specific item-based ratings, provide less valid findings.",
keywords = "Chronic depression, Nefazodone, Psychotherapy, Symptom measures",
author = "Rush, {A. John} and Trivedi, {Madhukar H.} and Carmody, {Thomas J.} and Ibrahim, {Hisham H.} and Markowitz, {John C.} and Keitner, {Gabor I.} and Kornstein, {Susan G.} and Bruce Arnow and Klein, {Daniel N.} and Rachel Manber and Dunner, {David L.} and Gelenberg, {Alan J.} and Kocsis, {James H.} and Nemeroff, {Charles B.} and Jan Fawcett and Thase, {Michael E.} and Russell, {James M.} and Jody, {Darlene N.} and Borian, {Frances O.} and Keller, {Martin B.}",
year = "2005",
month = "2",
doi = "10.1038/sj.npp.1300614",
language = "English (US)",
volume = "30",
pages = "405--416",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Self-reported depressive symptom measures

T2 - Sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients

AU - Rush, A. John

AU - Trivedi, Madhukar H.

AU - Carmody, Thomas J.

AU - Ibrahim, Hisham H.

AU - Markowitz, John C.

AU - Keitner, Gabor I.

AU - Kornstein, Susan G.

AU - Arnow, Bruce

AU - Klein, Daniel N.

AU - Manber, Rachel

AU - Dunner, David L.

AU - Gelenberg, Alan J.

AU - Kocsis, James H.

AU - Nemeroff, Charles B.

AU - Fawcett, Jan

AU - Thase, Michael E.

AU - Russell, James M.

AU - Jody, Darlene N.

AU - Borian, Frances O.

AU - Keller, Martin B.

PY - 2005/2

Y1 - 2005/2

N2 - This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-1) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-1, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a ≥50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-1 score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-1), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-1), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR 16), 73% (PGI-1), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30 = 32%, QIDS-SR 16 = 28%, PGI-1 = 22%, HDRS17 = 30%), for CBASP (IDS-SR30 = 32%, QIDS-SR16 = 30%, PGI-1 = 21%, HDRS 17 = 32%), and for the combination (IDS-SR30 = 52%, QIDS-SR16 = 50%, PGI-1 = 25%, HDRS17 = 49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-1, as opposed to specific item-based ratings, provide less valid findings.

AB - This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-1) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-1, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a ≥50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-1 score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-1), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-1), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR 16), 73% (PGI-1), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30 = 32%, QIDS-SR 16 = 28%, PGI-1 = 22%, HDRS17 = 30%), for CBASP (IDS-SR30 = 32%, QIDS-SR16 = 30%, PGI-1 = 21%, HDRS 17 = 32%), and for the combination (IDS-SR30 = 52%, QIDS-SR16 = 50%, PGI-1 = 25%, HDRS17 = 49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-1, as opposed to specific item-based ratings, provide less valid findings.

KW - Chronic depression

KW - Nefazodone

KW - Psychotherapy

KW - Symptom measures

UR - http://www.scopus.com/inward/record.url?scp=19944430673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944430673&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300614

DO - 10.1038/sj.npp.1300614

M3 - Article

C2 - 15578008

AN - SCOPUS:19944430673

VL - 30

SP - 405

EP - 416

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -